Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Clinical development of cancer therapeutics that target metabolism.
Journal: QJM : monthly journal of the Association of Physicians
Published: October 03, 2015
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Journal: Oncotarget
Published: August 14, 2014
6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.
Journal: Cell death & disease
Published: January 27, 2014
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
Journal: Cancer & metabolism
Published: August 14, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Journal: Molecular cancer therapeutics
Published: May 16, 2013
Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.
Journal: Journal of translational medicine
Published: January 26, 2012
Replication of damaged genomes.
Journal: Critical reviews in eukaryotic gene expression
Published: December 21, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026